二次性進行型多発性硬化症治療薬の世界市場（～2026年）

• 英文タイトル：Global Secondary Progressive Multiple Sclerosis Drug Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY09340
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、151ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は二次性進行型多発性硬化症治療薬のグローバル市場について調査・分析したレポートです。種類別（イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別二次性進行型多発性硬化症治療薬の競争状況、市場シェア
・世界の二次性進行型多発性硬化症治療薬市場：種類別市場規模 2015年-2020年（イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他）
・世界の二次性進行型多発性硬化症治療薬市場：種類別市場規模予測 2021年-2026年（イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他）
・世界の二次性進行型多発性硬化症治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他）
・世界の二次性進行型多発性硬化症治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他）
・北米の二次性進行型多発性硬化症治療薬市場分析：米国、カナダ
・ヨーロッパの二次性進行型多発性硬化症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの二次性進行型多発性硬化症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の二次性進行型多発性硬化症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの二次性進行型多発性硬化症治療薬市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：AB Science SA、Actelion Ltd、Biogen, Inc.、F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Glialogix, Inc.、Immune Response BioPharma, Inc.、Innate Immunotherapeutics Ltd、Kyorin Pharmaceutical Co., Ltd.、Mallinckrodt Plc、MedDay SA、MedImmune, LLC、Merck KGaA、Meta-IQ ApS、Novartis AG、Opexa Therapeutics, Inc.、Xenetic Biosciences (UK) Limited
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Secondary Progressive Multiple Sclerosis Drug Market
The global Secondary Progressive Multiple Sclerosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Secondary Progressive Multiple Sclerosis Drug Scope and Market Size
Secondary Progressive Multiple Sclerosis Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Secondary Progressive Multiple Sclerosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Secondary Progressive Multiple Sclerosis Drug market is segmented into
Inebilizumab
GLX-1112
DC-TAB
Etomoxir
IB-MS
Others

Segment by Application, the Secondary Progressive Multiple Sclerosis Drug market is segmented into
Hospital
Clinic
Others

Regional and Country-level Analysis
The Secondary Progressive Multiple Sclerosis Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Secondary Progressive Multiple Sclerosis Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Secondary Progressive Multiple Sclerosis Drug Market Share Analysis
Secondary Progressive Multiple Sclerosis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Secondary Progressive Multiple Sclerosis Drug business, the date to enter into the Secondary Progressive Multiple Sclerosis Drug market, Secondary Progressive Multiple Sclerosis Drug product introduction, recent developments, etc.

The major vendors covered:
AB Science SA
Actelion Ltd
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co., Ltd.
Mallinckrodt Plc
MedDay SA
MedImmune, LLC
Merck KGaA
Meta-IQ ApS
Novartis AG
Opexa Therapeutics, Inc.
Xenetic Biosciences (UK) Limited

レポート目次

1 Study Coverage
1.1 Secondary Progressive Multiple Sclerosis Drug Product Introduction
1.2 Market Segments
1.3 Key Secondary Progressive Multiple Sclerosis Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Type
1.4.2 Inebilizumab
1.4.3 GLX-1112
1.4.4 DC-TAB
1.4.5 Etomoxir
1.4.6 IB-MS
1.4.7 Others
1.5 Market by Application
1.5.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size, Estimates and Forecasts
2.1.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue 2015-2026
2.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales 2015-2026
2.2 Global Secondary Progressive Multiple Sclerosis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Secondary Progressive Multiple Sclerosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Secondary Progressive Multiple Sclerosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Secondary Progressive Multiple Sclerosis Drug Competitor Landscape by Players
3.1 Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers
3.1.1 Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers (2015-2020)
3.1.2 Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers
3.2.1 Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Secondary Progressive Multiple Sclerosis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Secondary Progressive Multiple Sclerosis Drug Revenue in 2019
3.2.5 Global Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Secondary Progressive Multiple Sclerosis Drug Price by Manufacturers
3.4 Secondary Progressive Multiple Sclerosis Drug Manufacturing Base Distribution, Product Types
3.4.1 Secondary Progressive Multiple Sclerosis Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Type
3.4.3 Date of International Manufacturers Enter into Secondary Progressive Multiple Sclerosis Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Type (2015-2020)
4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2015-2020)
4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2015-2020)
4.1.3 Secondary Progressive Multiple Sclerosis Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Secondary Progressive Multiple Sclerosis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Secondary Progressive Multiple Sclerosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Application (2015-2020)
5.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2015-2020)
5.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2015-2020)
5.1.3 Secondary Progressive Multiple Sclerosis Drug Price by Application (2015-2020)
5.2 Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Secondary Progressive Multiple Sclerosis Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Secondary Progressive Multiple Sclerosis Drug by Country
6.1.1 North America Secondary Progressive Multiple Sclerosis Drug Sales by Country
6.1.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Type
6.3 North America Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Secondary Progressive Multiple Sclerosis Drug by Country
7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country
7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Type
7.3 Europe Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug by Region
8.1.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region
8.1.2 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Type
8.3 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Secondary Progressive Multiple Sclerosis Drug by Country
9.1.1 Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country
9.1.2 Latin America Secondary Progressive Multiple Sclerosis Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Type
9.3 Central & South America Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug by Country
10.1.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country
10.1.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Type
10.3 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Facts & Figures by Application

11 Company Profiles
11.1 AB Science SA
11.1.1 AB Science SA Corporation Information
11.1.2 AB Science SA Description and Business Overview
11.1.3 AB Science SA Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Products Offered
11.1.5 AB Science SA Related Developments
11.2 Actelion Ltd
11.2.1 Actelion Ltd Corporation Information
11.2.2 Actelion Ltd Description and Business Overview
11.2.3 Actelion Ltd Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
11.2.5 Actelion Ltd Related Developments
11.3 Biogen, Inc.
11.3.1 Biogen, Inc. Corporation Information
11.3.2 Biogen, Inc. Description and Business Overview
11.3.3 Biogen, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
11.3.5 Biogen, Inc. Related Developments
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.4.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
11.4.5 F. Hoffmann-La Roche Ltd. Related Developments
11.5 Genzyme Corporation
11.5.1 Genzyme Corporation Corporation Information
11.5.2 Genzyme Corporation Description and Business Overview
11.5.3 Genzyme Corporation Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Products Offered
11.5.5 Genzyme Corporation Related Developments
11.6 Glialogix, Inc.
11.6.1 Glialogix, Inc. Corporation Information
11.6.2 Glialogix, Inc. Description and Business Overview
11.6.3 Glialogix, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
11.6.5 Glialogix, Inc. Related Developments
11.7 Immune Response BioPharma, Inc.
11.7.1 Immune Response BioPharma, Inc. Corporation Information
11.7.2 Immune Response BioPharma, Inc. Description and Business Overview
11.7.3 Immune Response BioPharma, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
11.7.5 Immune Response BioPharma, Inc. Related Developments
11.8 Innate Immunotherapeutics Ltd
11.8.1 Innate Immunotherapeutics Ltd Corporation Information
11.8.2 Innate Immunotherapeutics Ltd Description and Business Overview
11.8.3 Innate Immunotherapeutics Ltd Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
11.8.5 Innate Immunotherapeutics Ltd Related Developments
11.9 Kyorin Pharmaceutical Co., Ltd.
11.9.1 Kyorin Pharmaceutical Co., Ltd. Corporation Information
11.9.2 Kyorin Pharmaceutical Co., Ltd. Description and Business Overview
11.9.3 Kyorin Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
11.9.5 Kyorin Pharmaceutical Co., Ltd. Related Developments
11.10 Mallinckrodt Plc
11.10.1 Mallinckrodt Plc Corporation Information
11.10.2 Mallinckrodt Plc Description and Business Overview
11.10.3 Mallinckrodt Plc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Products Offered
11.10.5 Mallinckrodt Plc Related Developments
11.1 AB Science SA
11.1.1 AB Science SA Corporation Information
11.1.2 AB Science SA Description and Business Overview
11.1.3 AB Science SA Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Products Offered
11.1.5 AB Science SA Related Developments
11.12 MedImmune, LLC
11.12.1 MedImmune, LLC Corporation Information
11.12.2 MedImmune, LLC Description and Business Overview
11.12.3 MedImmune, LLC Sales, Revenue and Gross Margin (2015-2020)
11.12.4 MedImmune, LLC Products Offered
11.12.5 MedImmune, LLC Related Developments
11.13 Merck KGaA
11.13.1 Merck KGaA Corporation Information
11.13.2 Merck KGaA Description and Business Overview
11.13.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Merck KGaA Products Offered
11.13.5 Merck KGaA Related Developments
11.14 Meta-IQ ApS
11.14.1 Meta-IQ ApS Corporation Information
11.14.2 Meta-IQ ApS Description and Business Overview
11.14.3 Meta-IQ ApS Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Meta-IQ ApS Products Offered
11.14.5 Meta-IQ ApS Related Developments
11.15 Novartis AG
11.15.1 Novartis AG Corporation Information
11.15.2 Novartis AG Description and Business Overview
11.15.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Novartis AG Products Offered
11.15.5 Novartis AG Related Developments
11.16 Opexa Therapeutics, Inc.
11.16.1 Opexa Therapeutics, Inc. Corporation Information
11.16.2 Opexa Therapeutics, Inc. Description and Business Overview
11.16.3 Opexa Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Opexa Therapeutics, Inc. Products Offered
11.16.5 Opexa Therapeutics, Inc. Related Developments
11.17 Xenetic Biosciences (UK) Limited
11.17.1 Xenetic Biosciences (UK) Limited Corporation Information
11.17.2 Xenetic Biosciences (UK) Limited Description and Business Overview
11.17.3 Xenetic Biosciences (UK) Limited Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Xenetic Biosciences (UK) Limited Products Offered
11.17.5 Xenetic Biosciences (UK) Limited Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Secondary Progressive Multiple Sclerosis Drug Market Estimates and Projections by Region
12.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Regions 2021-2026
12.2 North America Secondary Progressive Multiple Sclerosis Drug Market Size Forecast (2021-2026)
12.2.1 North America: Secondary Progressive Multiple Sclerosis Drug Sales Forecast (2021-2026)
12.2.2 North America: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast (2021-2026)
12.2.3 North America: Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Secondary Progressive Multiple Sclerosis Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Secondary Progressive Multiple Sclerosis Drug Sales Forecast (2021-2026)
12.3.2 Europe: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Secondary Progressive Multiple Sclerosis Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Secondary Progressive Multiple Sclerosis Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Secondary Progressive Multiple Sclerosis Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Secondary Progressive Multiple Sclerosis Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Secondary Progressive Multiple Sclerosis Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Secondary Progressive Multiple Sclerosis Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Secondary Progressive Multiple Sclerosis Drug Market Segments
Table 2. Ranking of Global Top Secondary Progressive Multiple Sclerosis Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Inebilizumab
Table 5. Major Manufacturers of GLX-1112
Table 6. Major Manufacturers of DC-TAB
Table 7. Major Manufacturers of Etomoxir
Table 8. Major Manufacturers of IB-MS
Table 9. Major Manufacturers of Others
Table 10. Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Secondary Progressive Multiple Sclerosis Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Secondary Progressive Multiple Sclerosis Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Secondary Progressive Multiple Sclerosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Progressive Multiple Sclerosis Drug as of 2019)
Table 19. Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Price (2015-2020) (USD/Pcs)
Table 22. Secondary Progressive Multiple Sclerosis Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Type
Table 24. Date of International Manufacturers Enter into Secondary Progressive Multiple Sclerosis Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Type (2015-2020)
Table 28. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2015-2020)
Table 30. Secondary Progressive Multiple Sclerosis Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Application (2015-2020)
Table 33. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2015-2020)
Table 35. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2015-2020)
Table 39. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2015-2020)
Table 73. AB Science SA Corporation Information
Table 74. AB Science SA Description and Major Businesses
Table 75. AB Science SA Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. AB Science SA Product
Table 77. AB Science SA Recent Development
Table 78. Actelion Ltd Corporation Information
Table 79. Actelion Ltd Description and Major Businesses
Table 80. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Actelion Ltd Product
Table 82. Actelion Ltd Recent Development
Table 83. Biogen, Inc. Corporation Information
Table 84. Biogen, Inc. Description and Major Businesses
Table 85. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Biogen, Inc. Product
Table 87. Biogen, Inc. Recent Development
Table 88. F. Hoffmann-La Roche Ltd. Corporation Information
Table 89. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 90. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. F. Hoffmann-La Roche Ltd. Product
Table 92. F. Hoffmann-La Roche Ltd. Recent Development
Table 93. Genzyme Corporation Corporation Information
Table 94. Genzyme Corporation Description and Major Businesses
Table 95. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Genzyme Corporation Product
Table 97. Genzyme Corporation Recent Development
Table 98. Glialogix, Inc. Corporation Information
Table 99. Glialogix, Inc. Description and Major Businesses
Table 100. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Glialogix, Inc. Product
Table 102. Glialogix, Inc. Recent Development
Table 103. Immune Response BioPharma, Inc. Corporation Information
Table 104. Immune Response BioPharma, Inc. Description and Major Businesses
Table 105. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Immune Response BioPharma, Inc. Product
Table 107. Immune Response BioPharma, Inc. Recent Development
Table 108. Innate Immunotherapeutics Ltd Corporation Information
Table 109. Innate Immunotherapeutics Ltd Description and Major Businesses
Table 110. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Innate Immunotherapeutics Ltd Product
Table 112. Innate Immunotherapeutics Ltd Recent Development
Table 113. Kyorin Pharmaceutical Co., Ltd. Corporation Information
Table 114. Kyorin Pharmaceutical Co., Ltd. Description and Major Businesses
Table 115. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Kyorin Pharmaceutical Co., Ltd. Product
Table 117. Kyorin Pharmaceutical Co., Ltd. Recent Development
Table 118. Mallinckrodt Plc Corporation Information
Table 119. Mallinckrodt Plc Description and Major Businesses
Table 120. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Mallinckrodt Plc Product
Table 122. Mallinckrodt Plc Recent Development
Table 123. MedDay SA Corporation Information
Table 124. MedDay SA Description and Major Businesses
Table 125. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. MedDay SA Product
Table 127. MedDay SA Recent Development
Table 128. MedImmune, LLC Corporation Information
Table 129. MedImmune, LLC Description and Major Businesses
Table 130. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. MedImmune, LLC Product
Table 132. MedImmune, LLC Recent Development
Table 133. Merck KGaA Corporation Information
Table 134. Merck KGaA Description and Major Businesses
Table 135. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. Merck KGaA Product
Table 137. Merck KGaA Recent Development
Table 138. Meta-IQ ApS Corporation Information
Table 139. Meta-IQ ApS Description and Major Businesses
Table 140. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 141. Meta-IQ ApS Product
Table 142. Meta-IQ ApS Recent Development
Table 143. Novartis AG Corporation Information
Table 144. Novartis AG Description and Major Businesses
Table 145. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 146. Novartis AG Product
Table 147. Novartis AG Recent Development
Table 148. Opexa Therapeutics, Inc. Corporation Information
Table 149. Opexa Therapeutics, Inc. Description and Major Businesses
Table 150. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 151. Opexa Therapeutics, Inc. Product
Table 152. Opexa Therapeutics, Inc. Recent Development
Table 153. Xenetic Biosciences (UK) Limited Corporation Information
Table 154. Xenetic Biosciences (UK) Limited Description and Major Businesses
Table 155. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 156. Xenetic Biosciences (UK) Limited Product
Table 157. Xenetic Biosciences (UK) Limited Recent Development
Table 158. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 159. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Regions (2021-2026)
Table 160. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 161. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 162. North America: Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 163. North America: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 164. Europe: Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 165. Europe: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 166. Asia Pacific: Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 167. Asia Pacific: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 168. Latin America: Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 169. Latin America: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 170. Middle East and Africa: Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 171. Middle East and Africa: Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 172. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 173. Key Challenges
Table 174. Market Risks
Table 175. Main Points Interviewed from Key Secondary Progressive Multiple Sclerosis Drug Players
Table 176. Secondary Progressive Multiple Sclerosis Drug Customers List
Table 177. Secondary Progressive Multiple Sclerosis Drug Distributors List
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Secondary Progressive Multiple Sclerosis Drug Product Picture
Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Inebilizumab Product Picture
Figure 4. GLX-1112 Product Picture
Figure 5. DC-TAB Product Picture
Figure 6. Etomoxir Product Picture
Figure 7. IB-MS Product Picture
Figure 8. Others Product Picture
Figure 9. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Secondary Progressive Multiple Sclerosis Drug Report Years Considered
Figure 14. Global Secondary Progressive Multiple Sclerosis Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region in 2019
Figure 19. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region in 2019
Figure 21. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Secondary Progressive Multiple Sclerosis Drug Revenue in 2019
Figure 23. Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2019
Figure 26. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type in 2019
Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Price Range (2015-2020)
Figure 29. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2019
Figure 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application in 2019
Figure 33. North America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2019
Figure 36. North America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Secondary Progressive Multiple Sclerosis Drug Market Share by Type in 2019
Figure 42. North America Secondary Progressive Multiple Sclerosis Drug Market Share by Application in 2019
Figure 43. Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2019
Figure 46. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country in 2019
Figure 47. Germany Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Secondary Progressive Multiple Sclerosis Drug Market Share by Type in 2019
Figure 58. Europe Secondary Progressive Multiple Sclerosis Drug Market Share by Application in 2019
Figure 59. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region in 2019
Figure 63. China Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Share by Type in 2019
Figure 86. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Market Share by Application in 2019
Figure 87. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2019
Figure 90. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Secondary Progressive Multiple Sclerosis Drug Market Share by Type in 2019
Figure 98. Latin America Secondary Progressive Multiple Sclerosis Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Share by Application in 2019
Figure 111. North America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed

以下、関連資料のご紹介

進行型再発性多発性硬化症治療の世界市場（～2026年）

Global Progressive Relapsing Multiple Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04381 2020年11月20日 97Pages
当調査資料は進行型再発性多発性硬化症治療のグローバル市場について調査・分析したレポートです。種類別（COG-133、GZ-402668、イネビリズマブ、VCE-0032、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

一次進行型多発性硬化症治療の世界市場（～2026年）

Global Primary Progressive Multiple Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04371 2020年11月20日 92Pages
当調査資料は一次進行型多発性硬化症治療のグローバル市場について調査・分析したレポートです。種類別（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、...

多発性硬化症における幹細胞治療の世界市場（～2026年）

Global Stem Cell Therapy for Multiple Sclerosis Market Size, Status and Forecast 2020-2026
MRC2-11QY04730 2020年11月20日 97Pages
当調査資料は多発性硬化症における幹細胞治療のグローバル市場について調査・分析したレポートです。種類別（静脈内、脳室内）市場規模、用途別（再発寛解型多発性硬化症（RRMS）、一次進行型多発性硬化症（PPMS）、二次性進行型多発性硬化症（SPMS）、進行型再発性多発性硬化症（PRMS））市場規模、地域別...

多発性硬化症治療の世界市場（～2026年）

Global Multiple Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY03867 2020年11月20日 99Pages
当調査資料は多発性硬化症治療のグローバル市場について調査・分析したレポートです。種類別（磁気共鳴画像法、簡易電気刺激検査、腰椎穿刺）市場規模、用途別（獣医病院、獣医クリニック、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国...

多発性硬化症治療薬の世界市場（～2026年）

Global Multiple Sclerosis Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY03866 2020年11月20日 95Pages
当調査資料は多発性硬化症治療薬のグローバル市場について調査・分析したレポートです。種類別（ベータインターフェロン、コルチコステロイド、モノクローナル抗体、抗腫瘍剤、その他）市場規模、用途別（病院薬局、小売薬局、eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

進行性多巣性白質脳症治療薬の世界市場（～2026年）

Global Progressive Multifocal Leukoencephalopathy Drug Market Insights and Forecast to 2026
MRC2-11QY14414 2020年11月30日 114Pages
当調査資料は進行性多巣性白質脳症治療薬のグローバル市場について調査・分析したレポートです。種類別（EBT-103、IKT-01427、メシル酸イマチニブ、NI-307、その他）市場規模、用途別（病院、診療所、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

進行性多巣性白質脳症治療の世界市場（～2026年）

Global Progressive Multifocal Leukoencephalopathy Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04380 2020年11月20日 90Pages
当調査資料は進行性多巣性白質脳症治療のグローバル市場について調査・分析したレポートです。種類別（抗レトロウイルス療法、抗ウイルス/抗JCV、その他の症状）市場規模、用途別（病院薬局、ドラッグストア、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシ...

筋萎縮性側索硬化症（ALS）の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis Market Size, Status and Forecast 2020-2026
MRC2-11QY10829 2020年11月25日 91Pages
当調査資料は筋萎縮性側索硬化症（ALS）のグローバル市場について調査・分析したレポートです。種類別（幹細胞治療、化学療法）市場規模、用途別（病院、診断センター、診療所、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、...

筋萎縮性側索硬化症（ルーゲーリック病）治療の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY10827 2020年11月25日 93Pages
当調査資料は筋萎縮性側索硬化症（ルーゲーリック病）治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、幹細胞治療）市場規模、用途別（病院、診断センター、診療所、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本...

筋萎縮性側索硬化症（ALS）治療の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY10830 2020年11月25日 90Pages
当調査資料は筋萎縮性側索硬化症（ALS）治療のグローバル市場について調査・分析したレポートです。種類別（薬物療法、理学療法、言語療法、その他）市場規模、用途別（病院、専門センター、研究センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、ア...

進行型再発性多発性硬化症治療の世界市場（～2026年） Market Analysis and Insights: Global Progressive Relapsing Multiple Sclerosis Treatment Market The global Progressive Relapsing Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Progressive R…
一次進行型多発性硬化症治療の世界市場（～2026年） Market Analysis and Insights: Global Primary Progressive Multiple Sclerosis Treatment Market The global Primary Progressive Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Primary Progressi…
多発性硬化症における幹細胞治療の世界市場（～2026年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
多発性硬化症治療の世界市場（～2026年） Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and somet…
多発性硬化症治療薬の世界市場（～2026年） Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the d…